Table 1.
Distribution of demographics, HIV disease factors, history of statin and nonstatin lipid-lowering therapy use, and co-morbidity among non-Hodgkin lymphoma cases and controls.
| Controls (N =1295) | NHL cases (N =259) | ||
|---|---|---|---|
| Number (%) or mean (SD) | P value | ||
| Agea mean (SD, years) | 43.1 (8.9) | 43.2 (8.9) | – |
| Male sexa | 1240 (95.8%) | 248 (95.8%) | – |
| Racea | |||
| White | 775 (59.9%) | 155 (59.9%) | – |
| Nonwhite | 520 (40.2%) | 104 (40.2%) | |
| History of statin use | |||
| Ever use | 177 (13.7%) | 21 (8.1%) | 0.01 |
| Nonregular use (<12 mos continuous use) | 154 (11.9%) | 18 (7.0%) | 0.05 |
| Regular use (≥12 mos continuous use) | 23 (1.8%) | 3 (1.2%) | |
| Short-term use (<12 mos cumulative use) | 75 (5.8%) | 10 (3.9%) | 0.05 |
| Long-term use (≥12 mos cumulative use) | 97 (7.5%) | 11 (4.3%) | |
| Among those ever used statins | |||
| Duration of use (mos), mean (SD) | 22.4 (22.9) | 19.7 (17.6) | –b |
| Duration of lipophilic statin use (mos)b, mean (SD) | 20.0 (21.8) | 19.0 (19.1) | –b |
| Duration of hydrophilic statin use (mos)b, mean (SD) | 17.2 (18.5) | 15.3 (12.2) | –b |
| Type of statin (% among dispensed statin prescriptions) | |||
| Atorvastatin | 37.4% | 21.7% | –b |
| Lovastatin | 14.4% | 35.5% | –b |
| Simvastatin | 20.7% | 20.8% | –b |
| Pravastatin | 27.5% | 22.0% | –b |
| History of nonstatin lipid-lowering therapy use | |||
| Ever use | 96 (7.4%) | 13 (5.0%) | 0.17 |
| Nonregular use (<12 mos continuous use) | 88 (6.8%) | 11 (4.3%) | 0.30 |
| Regular use (≥12 mos continuous use) | 8 (0.6%) | 2 (0.8%) | |
| Short-term use (<12 mos cumulative use) | 64 (4.9%) | 9 (3.5%) | 0.38 |
| Long-term use (≥12 mos cumulative use) | 32 (2.5%) | 4 (1.5%) | |
| Among those ever used nonstatin lipid-lowering therapy Duration of useb (mos), mean (SD) | 15.0 (19.7) | 11.8 (14.2) | –b |
| Baseline CD4 cell count | |||
| Mean (SD) | 376 (295) | 246 (213) | <0.0001 |
| ≤200/µl | 288 (22.2%) | 96 (37.1%) | <0.0001 |
| 201–500/µl | 397 (30.7%) | 74 (28.6%) | |
| >500/µl | 254 (19.6%) | 19 (7.3%) | |
| Unknown | 356 (27.5%) | 70 (27.0%) | |
| Baseline HIV RNA level | |||
| ≤500 copies/ml | 221 (17.11%) | 14 (5.4%) | <0.0001 |
| 501–10 000 copies/ml | 124 (9.6%) | 25 (9.7%) | |
| >10 000 copies/ml | 217 (16.8%) | 74 (28.6%) | |
| Unknown | 733 (56.6%) | 146 (56.4%) | |
| Duration of ART use (years) | 1.7 (2.3) | 1.3 (2.0) | 0.01 |
| Clinical AIDS diagnosis prior to index | 123 (9.5%) | 33 (12.7%) | 0.11 |
| History of co-morbidity | |||
| Hepatitis B | 17 (1.3%) | 5 (1.9%) | 0.44 |
| Hepatitis C | 33 (2.6%) | 7 (2.7%) | 0.89 |
| Diabetes | 41 (3.2%) | 8 (3.1%) | 0.95 |
| Obesity | 36 (2.8%) | 12 (4.6%) | 0.12 |
| NHL subtype | |||
| Diffuse large B-cell lymphoma | – | 167 (64.5%) | – |
| Burkitt’s lymphoma | – | 41 (15.8%) | |
| Follicular lymphoma | – | 2 (0.8%) | |
| Other | – | 49 (18.9%) | |
ART, antiretroviral therapy; mos, months; NHL, non-Hodgkin lymphoma.
a
Matching factors.
b
P value not provided because measures were calculated for statin or nonstatin lipid-lowering therapy users only.